Front-line treatment with obinutuzumab ± chlorambucil for chronic lymphocytic leukemia in real-world clinical practice: results of a multinational, multicenter study by Eric and Icllsg. [AUT.] YAIR HERISHANU, ADIR SHAULOV, RIVA FINEMAN, SANDRA BAŠIC-KINDA, ARIEL AVIV, EWA WĄSIK-SZCZEPANEK, OZREN JAKSIC, MIHNEA ZDRENGHEA, URI GREENBAUM, INGA MANDAC, MARTIN ŠIMKOVIČ, MARTA MORAWSKA, OHAD BENJAMINI, MARTIN ŠPAČEK, ANATOLY NEMETS, OSNAT BAIREY, ANDREA VISENTIN, ROSA RUCHLEMER, LUCA LAURENTI, OANA STANCA CIOCAN, MICHAEL DOUBEK, LEV SHVIDEL, NAGIB DELI, FATIMA MIRAS CALVO, ANNE DE MEÛTER, MARIA DIMOU, FRANCESCA ROMANA MAURO, MARTA COSCIA, HORIA BUMBEA, SZÁSZ RÓBERT, TAMAR TADMOR, ODIT GUTWEIN, MASSIMO GENTILE, LYDIA SCARFÒ, ALESSANDRA TEDESCHI, PAOLO SPORTOLETTI, EVA GIMENO VÁZQUEZ, JUAN MARQUET PALOMANES, SARIT ASSOULINE, MARIA PAPAIOANNOU, ANDREI BREASTER, LUCIANO LEVATO, MICHAEL GREGOR, GIAN MATTEO RIGOLIN, JAVIER LOSCERTALES, ANGELES MEDINA PEREZ, MARTEN R. NIJZIEL, VIOLA MARIA POPOV, ROSA COLLADO, IRMA SLAVUTSKY, SHAI LEVI, AARON POLLIACK, PAOLO GHIA. Blood [online] 2019 vol. 134 suppl. 1 [b. pag.] 1766, 61st ASH Annual Meeting and Exposition. Orlando, December 7-10, 2019 [online]. Abstr. [przeglądany 6 listopada 2023]. Dostępny w: https://ashpublications.org/blood/article/134/Supplement_1/1766/427561/Front-Line-Treatment-with-Obinutuzumab. DOI: 10.1182/blood-2019-122309

✓ Skopiowane!